Abstract: The present invention discloses polypeptides and related substances against hair loss and dermatitis, and the uses thereof. Particularly, disclosed is the use of an osteocalcin-derived peptide, and homologous polypeptides, polypeptide-derived peptides or derivatives of the polypeptides and polypeptide-derived peptides, which use the osteocalcin-derived peptide as a skeleton and which are derived from different species, in preparing drugs for treating hair follicle recession and/or hair loss caused by psychological stress, seborrheic hair follicle recession and/or hair loss, acne and/or dermatitis caused by psychological stress and seborrheic acne and/or dermatitis. Further disclosed are the use, in preparing drugs, medical cosmetology products, cosmetics, health-care products, foods and additives for preventing and/or treating hair follicle recession, hair loss, acne and dermatitis, of substances capable of binding to a GPR158 receptor and modulating its activity.

Abstract: Labels that include dibromopyridazinedione attached to signal molecules are disclosed, along with methods of producing and using same. Also disclosed are conjugates of the label attached to an analyte-specific binder, as well as methods of producing and using same. Kits containing the labels and/or conjugates are also disclosed, along with microfluidics devices containing same.

Abstract: The present invention discloses a shoreline structure and a construction method thereof, the structure includes a wave-absorbing submerged breakwater, a soil embankment, a shallow beach area, a deep-water ditch, and planting platforms. The wave-absorbing submerged breakwater includes a first gabion box and a first emergent plant on the top; the shallow beach area includes a third emergent plant; the deep-water ditch is located between the shallow beach area and the wave-absorbing submerged breakwater, and includes a submerged plant; planting platforms are dispersed within the deep-water ditch, and have a second emergent plant. The present invention dissipates the wind and waves on the shoreline slope through the wave-absorbing submerged breakwater, and the planting platforms are dotted in the deep-water ditch, creating wetland habitats alternating between deep and shallow water, and a near-shore waterfront wetland environment to purify and maintain the water quality of the lakes and reservoirs.

Abstract: Provided are an ovary-targeting polypeptide, a derivative of the polypeptide, and the use of the polypeptide in the preparation of a drug or reagent for treating ovarian related reproductive diseases and preventing and treating the in-vivo or in-vitro aging of oocytes. The diseases comprise menstrual cycle disorder, polycystic ovary syndrome, androgenic phenotype, hair loss, abnormal metabolism, ovarian insufficiency, premature ovarian failure, ovulation failure, abnormal glucose metabolism, and abnormal lipid metabolism, preferably, hyperglycemia and insulin resistance. In addition, the polypeptide is expected to prolong the preservation time and improve the preservation quality of oocytes or fertilized eggs in the field of assisted reproduction.

Abstract: Labels that include dibromopyridazinedione attached to signal molecules are disclosed, along with methods of producing and using same. Also disclosed are conjugates of the label attached to an analyte-specific binder, as well as methods of producing and using same. Kits containing the labels and/or conjugates are also disclosed, along with microfluidics devices containing same.

Abstract: The present invention relates to multi-hapten mutant G6PDH conjugates, methods of their preparation and their use for detection of multiple analytes. The compositions of the invention comprise different types of haptens (molecules) require to be immobilized into the G6PDH to make one multi-hapten-G6PDH conjugate. Both thiol and amine functional groups on G6PDH are utilized for immobilization of different haptens.

Abstract: Compositions, methods, and kits are disclosed directed at haptens, immunogens and immunoassays for oxycodone and metabolites thereof. The compounds are exemplified by compounds of the Formula I. The method comprises providing in combination in a medium (i) a sample suspected of containing oxycodone and/or oxycodone metabolites, a compound of the Formula I wherein R4 or R5 is a label, and an antibody for oxycodone or a metabolite thereof. The medium is examined for the presence of a complex comprising the labeled compound of Formula I where the presence of such as complex indicates the presence of oxycodone or oxycodone metabolite in the sample.

Abstract: The present invention relates to multi-hapten mutant G6PDH conjugates, methods of their preparation and their use for detection of multiple analytes. The compositions of the invention comprise different types of haptens (molecules) require to be immobilized into the G6PDH to make one multi-hapten-G6PDH conjugate. Both thiol and amine functional groups on G6PDH are utilized for immobilization of different haptens.

Abstract: A reagent kit used for detecting gastrin-17, a preparation method, and a detection method for the reagent kit. The reagent kit comprises component A and component B, wherein component A is a first anti-gastrin-17 antibody marked with a trace marker or coated on magnetic spheres, and component B is a second gastrin-17 antibody or gastrin-17 coated on magnetic spheres or marked with a trace marker. Either one of component A and component B is marked with the trace marker, and the other one is coated on the magnetic spheres. The first gastrin-17 antibody and gastrin-17 binding site is different from the second gastrin-17 antibody and gastrin-17 binding site. The method using a double antibody sandwich method or a competition method to detect gastrin-17 accurately and sensitively measures the amount of gastrin-17 in a sample.

Abstract: Compositions, methods, and kits are disclosed directed at haptens, immunogens and immunoassays for oxycodone and metabolites thereof. The compounds are exemplified by compounds of the Formula I. The method comprises providing in combination in a medium (i) a sample suspected of containing oxycodone and/or oxycodone metabolites, a compound of the Formula I wherein R4 or R5 is a label, and an antibody for oxycodone or a metabolite thereof. The medium is examined for the presence of a complex comprising the labeled compound of Formula I where the presence of such as complex indicates the presence of oxycodone or oxycodone metabolite in the sample.

Abstract: A polymer consisting of a regio-regular polymer backbone basing on asymmetric fluorine-substituted 2,1,3-benzothiadiazole units (FBT) having a Formula 1MP0: where. R1 is any alkyl group of 1-30 carbons; R2 is any alkyl group of 1-30 carbons; n is any number greater than 6; D is an aryl moiety.

Abstract: A polymer consisting of a regio-regular polymer backbone basing on asymmetric fluorine-substituted 2,1,3-benzothiadiazole units (FBT) having a Formula 1MP0: where. R1 is any alkyl group of 1-30 carbons; R2 is any alkyl group of 1-30 carbons: n is any number greater than 6; D is an aryl moiety.

Abstract: The present invention relates to multi-hapten mutant G6PDH conjugates, methods of their preparation and their use for detection of multiple analytes. The compositions of the invention comprise different types of haptens (molecules) require to be immobilized into the G6PDH to make one multi-hapten-G6PDH conjugate. Both thiol and amine functional groups on G6PDH are utilized for immobilization of different haptens.

Abstract: Preparation and application of poly[[2,6?-4,8-di(5-ethylhexylthienyl)benzo[1,2-b;3,3-b]dithiophene][3-fluoro-2[(2-ethylhexyl)carbonyl]thieno[3,4-b]thiophenediyl]] as a semiconducting polymer.

Abstract: The invention provides a method for producing a PTC ink composition, which is capable of adjusting the switching temperature (Ts) of the PTC ink composition by addition of some additives. The content of the additive based on the total PTC composition for adjusting the Ts is less than 5.0 wt. %. The additives for adjusting the Ts can be chosen from polyester, polyether, and poly(ethylene glycol) with low molecular weight from 300 to 3000 g/mol.

Abstract: Compounds are disclosed comprising a moiety, such as a poly(amino acid), a non-poly(amino acid) label moiety, or a non-poly(amino acid) immunogenic carrier, linked to a sirolimus compound at position 26 or at position 32. Such sirolimus compounds comprising an immunogenic carrier can be employed to raise both polyclonal and monoclonal antibodies to the sirolimus compound. Polyclonal antibodies are also disclosed, which are raised against a compound wherein a moiety, such as a poly(amino acid), a non-poly(amino acid) label moiety, or a non-poly(amino acid) immunogenic carrier, is linked to a sirolimus compound at position 32. The above antibodies and sirolimus compounds comprising a label can be used in assays for the detection of sirolimus compounds.

Abstract: Compounds are disclosed comprising a moiety, such as a poly(amino acid), a non-poly(amino acid) label moiety, or a non-poly(amino acid) immunogenic carrier, linked to a sirolimus compound at position 26 or at position 32. Such sirolimus compounds comprising an immunogenic carrier can be employed to raise both polyclonal and monoclonal antibodies to the sirolimus compound. Polyclonal antibodies are also disclosed, which are raised against a compound wherein a moiety, such as a poly(amino acid), a non-poly(amino acid) label moiety, or a non-poly(amino acid) immunogenic carrier, is linked to a sirolimus compound at position 32. The above antibodies and sirolimus compounds comprising a label can be used in assays for the detection of sirolimus compounds.

Abstract: Methods, compositions and kits are disclosed. Enzyme conjugates of Formula I are employed in assays for the determination of an methylenedioxyamphetamine, a methylene-dioxyethamphetamine, and/or a methylenedioxymethamphetamine. Immunogenic conjugates of Formula I are employed to prepare antibodies for an methylenedioxyamphetamine, a methylenedioxyethamphetamine, and/or for a methylene-dioxymethamphetamine for use in assays for the determination of an methylenedioxyamphetamine, a methylenedioxyethamphetamine, and/or a methylene-dioxymethamphetamine. The enzyme conjugates may also be employed to screen antibodies for use in such methods.

Abstract: Methods, compositions and kits are disclosed. Enzyme conjugates of Formula I are employed in assays for the determination of an methylenedioxyamphetamine, a methylene-dioxyethamphetamine, and/or a methylenedioxymethamphetamine. Immunogenic conjugates of Formula I are employed to prepare antibodies for an methylenedioxyamphetamine, a methylenedioxyethamphetamine, and/or for a methylene-dioxymethamphetamine for use in assays for the determination of an methylenedioxyamphetamine, a methylenedioxyethamphetamine, and/or a methylene-dioxymethamphetamine. The enzyme conjugates may also be employed to screen antibodies for use in such methods.

Abstract: Methods, compositions and kits are disclosed. The methods are directed to determining the presence of entactogen analytes such as, for example, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), 3,4-methylenedioxy-ethylamphetamine (MDEA) and 4-hydroxy-3-methoxy-methamphetamine (HMMA). The method comprises providing in combination in a medium (i) a sample suspected of containing the compound and (ii) an antibody raised against a compound of Formula I that comprises a protein. The medium is examined for the presence a complex comprising the compound and the antibody where the presence of such as complex indicates the presence of the compound in the sample. In one aspect of the above embodiment, the combination further comprises a label conjugate of the compound Formula I.